Skip to main content

Table 9 Baseline characteristics of patients with HAM/TSP who had been observed for four years (n = 148)

From: Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan

 

All patients

(n = 148)

Steroid (S) group

(n = 47)

Steroid-

history

(SH) group

(n = 36)

Untreated (U) group

(n = 32)

Miscella-

neous (M) group

(n = 33)

p value

Groups with significant difference c)

Sex: Female

112

(75.7%)

36

(76.6%)

25

(69.4%)

24

(75.0%)

27

(81.8%)

0.690 a)

Age at baseline (year)d

61.8 ± 9.7

63.0 ± 7.5

61.4 ± 9.7

60.6 ± 12.4

61.5 ± 9.7

0.740 b)

Age at onset (year)d

43.4 ± 14.4

47.5 ± 13.0

40.5 ± 15.2

42.2 ± 13.1

41.7 ± 15.7

0.113 b)

Disease durationd (Time from onset to initial interview)

17.5 ± 10.4

15.7 ± 9.4

19.8 ± 10.0

16.6 ± 10.6

18.3 ± 11.9

0.300 b)

Baseline OMDSd

5.8 ± 2.2

6.0 ± 2.3

6.6 ± 2.4

4.8 ± 1.4

5.7 ± 2.1

0.012 b)

SH > U

Rapid progressorse

21 (14.2%)

10 (21.3%)

5 (13.9%)

3 (9.4%)

3 (9.1%)

0.354 a)

  1. Statistical methods: a) By chi-square test, b) By analysis of variance, c) By Tukey post hoc tests
  2. dData are expressed as mean ± standard deviation, e Rapid progressors were defined as those who developed OMDS 5 or above within 2 years from the onset of motor symptoms. Abbreviation: OMDS, Osame motor disability score